



“New Frontiers in Ocular Therapeutics”

(UCD, Conway Institute, Lecture Theatre 12th and 13th of October 2015)

Day1. (Monday 12th) **10.00 - 10.30 hrs Registration and Posters/Coffee** (Conway Foyer)

I. Ocular Disease & Treatment

Chaired by **Dr. Breandán Kennedy** (10.30 - 12.10 hrs)

- **Prof Andrew Lotery.** Professor of Ophthalmology, University of Southampton. Lead of Clinical Trials Group (commercial and NHS funded). Principal Investigator on different charity funded research. Southampton, UK. *“What patients want”*
- **Dr Paul Kenna.** Research Ophthalmologist. The Research Foundation, The Royal Victoria Eye and Ear Hospital Dublin and The Ocular Genetics Unit, Trinity College Dublin (Ireland). *“Autosomal Dominant Retinitis Pigmentosa”*
- **Dr David Kent.** Consultant Ophthalmologist. The Vision Clinic, Kilkenny (Ireland). *“Inflammation and the Retina: is it always bad?”*
- **Prof Alan Bird.** Honorary Consultant Ophthalmologist at the Moorfields Eye Hospital; Emeritus Professor, Institute Of Ophthalmology, University College London (UK). *“Selection of early AMD patients for clinical trials: more than one disease”*
- **Panel Discussion**

12.10-13.00 LUNCH AND POSTERS (Conway Foyer) / *(Optional: Tour of Conway Facilities)*

II. Ocular Drug Discovery

Chaired by **Dr Alison Reynolds UCD** (13.00 - 14.40 hrs)

- **Dr Breandan Kennedy.** Senior Lecturer and Principal Investigator in UCD SBBS – Conway Institute, University College Dublin (Ireland). *“Phenotype based discovery of novel drugs for blindness”*
- **Dr Javier Terriente.** Chief Science Officer in Ze-Clinics, Barcelona (Spain). *“ZeClinics. Drug discovery through zebrafish”*
- **Dr Torsen Meiners.** EU Openscreen Communications Manager. FMP Leibniz-Institute of Molecular Pharmacology, Berlin (Germany). *“EU-OPENSREEN - Facilities for drugscreening”*
- **Dr Alfonso Blanco.** Director of Conway Core Facilities, UCD SBBS – Conway Institute, University College Dublin (Ireland). *“How can Cytomics help you in Drug Discovery?”*
- **Panel Discussion**

14.40-15.10 COFFEE BREAK / POSTER SESSION (Conway Foyer)

III. Ocular Drug Development I & Drug Delivery

Chaired by **Prof David Brayden UCD** (15.10 – 17.10 hrs)

- **Showcase of Young Investigators I** (**Denise Moran, Dr Orla Galvin, Stephanie Merrigan**)
- **Dr Thakur Raghu Raj Singh.** Lecturer in Pharmaceutics in the School of Pharmacy and PI in Advanced Polymeric Drug Delivery Systems, Queen's University Belfast (UK). *“Minimally-Invasive and long-acting ocular drug delivery strategies”*
- **Prof Abhay Pandit.** Professor of Biomedical Engineering at National University of Ireland, Galway (Ireland). *“Understanding the host for designing drug delivery systems”*
- **Prof Clive G. Wilson.** E.F.A.P.S., F.C.R.S., J P Todd Professor of Pharmaceutics. Education Liaison & Senate, European Federation for Pharmaceutical Sciences. Strathclyde Institute of Pharmacy and Biomedical Sciences Glasgow, Scotland (UK). *“Do we have the hand to win the game?”*
- **Prof Brendan Buckley.** ICON Chief Medical Officer, Dublin (Ireland). *“Bringing discoveries from the bench into man in a regulated world”*
- **Panel Discussion**

IV. 17.30-19.00 3DNET Management Meeting /H2020 opportunities (Conway Boardroom)

19.30 Workshop DINNER (registration required)



Day2. (Tuesday 13th)

V. Ocular Drug Development II. Preclinical Models and Clinical Trials

Chaired by Dr. Yolanda Alvarez (9.00 – 11.00 hrs)

- **Dr Brian Fennell.** PI in Global Biotherapeutics Technologies, Pfizer. Dublin (Ireland). “Multi-parametric optimisation and characterisation of antibody binding domains for chronic dosing.”
- **Dr Robert Haigh.** Chief Operating Officer at KalVista, Porton Down (UK). “Plasma kallikrein as a target in diabetic macular edema”
- **Dr Rob Jones.** Co-founder of the SME and Diabetes Project Manager at the CRO RenaSci, Nottingham (UK). “Preclinical Models to study Obesity and Diabetes”
- **Showcase of Young Investigators II (Dr Anna Sophie Kiang, Conor Daly, Dr Ashleigh Byrne, Dr Lasse Jensen, Dr Alison Reynolds) 10.15 hrs**

COFFEE BREAK/ POSTER SESSION/ COLLABORATION OPPORTUNITIES (Conway Foyer/Conway Boardroom) (11.00 – 12.00 hrs)

VI. Plenary lecture / Conway Class Seminar Conway Lecture Th. (12.00 – 13.00 hrs)

Prof Yihai Cao. Professor at the Microbiology and Tumor Biology Center in Karolinska Institutet and founder of Clanotech, Stockholm (Sweden). “Targeting angiogenesis and fibrosis for treatment of eye disease”



SHOWCASE OF YOUNG INVESTIGATORS: I (12 Oct at 15.10 hrs) and II (13 Oct at 9.30 hrs)

- **Denise Moran.** Centre for Synthesis & Chemical Biology, SCCB, University College Dublin (Ireland). “Stable Lipoxin Analogues for Biological Evaluation”
- **Dr Orla Galvin.** UCD SBBS UCD Conway Institute, University College Dublin (Ireland). “Hyaluronic Acid Microneedles allow for sustained release of Anti-Angiogenic Quininib”
- **Stephanie Merrigan.** UCD SBBS UCD Conway Institute, University College Dublin (Ireland). “Vitamin D Receptor Agonists Significantly Attenuate Ocular Developmental Angiogenesis”
- **Dr Anna Sophia Kiang.** Ocular Genetics Unit, Smurfit Institute of Genetics, Trinity College Dublin (Ireland). “Enhanced drug delivery to rodent retinas following inner blood-retina barrier modulation”
- **Conor Daly.** UCD SBBS UCD Conway Institute, University College Dublin (Ireland). “Pharmacological Restoration of Visual Function in a Blind Zebrafish Mutant Following Histone Deacetylase Inhibitor (HDACi) Treatment”
- **Dr Ashleigh Byrne.** Cell Development and Disease Laboratory, Biochemistry Department, Biosciences Institute, University College Cork, (Ireland). “Norgestrel: a progesterone analogue; acts as a neuroprotectant in two mouse models of Retinitis Pigmentosa”
- **Dr Lasse Jensen.** Department of Medical and Health Sciences, Division of Cardiovascular Medicine, Linköping University, Linköping, (Sweden). “Fundamental differences between choroidal and retinal neovascularization revealed in novel zebrafish ocular angiogenesis models”
- **Dr Alison L. Reynolds.** UCD SBBS UCD Conway Institute, University College Dublin (Ireland). “Phenotype-Based Discovery of 2-[(E)-2-(Quinolin-2-Yl)Vinyl]Phenol as a Novel Inhibitor of Developmental and Pathological Ocular Angiogenesis”